Abstract
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / blood
-
Anti-Bacterial Agents / therapeutic use*
-
Colony Count, Microbial
-
Endocarditis, Bacterial / drug therapy*
-
Endocarditis, Bacterial / microbiology
-
Glycopeptides
-
Kidney / microbiology
-
Lipoglycopeptides
-
Male
-
Methicillin Resistance*
-
Rabbits
-
Spleen / microbiology
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
-
Vancomycin / blood
-
Vancomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Glycopeptides
-
Lipoglycopeptides
-
Vancomycin
-
oritavancin